Policy & Regulation
Viking Therapeutics plans offerings of common stock and convertible senior notes
24 September 2026 - Viking Therapeutics Inc (Nasdaq:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced on ...
Astellas doses first patient in Phase 3 lung cancer study
24 September 2026 - Japanese pharmaceutical company Astellas Pharma Inc (TSE:4503) announced on Wednesday that the first patient has been dosed in a Phase 3 study evaluating setidegrasib, a novel, inv...
AstraZeneca's Trixeo Aerosphere approved in EU for asthma maintenance treatment
23 September 2026 - Biopharmaceutical company AstraZeneca (LSE: AZN) (STO: AZN) (NYSE: AZN) declared on Wednesday that it has received European Commission approval for Trixeo Aerosphere as a maintenan...
Ondine Biomedical deployssteriwave across five Southern Ontario hospitals
23 September 2026 - Canadian life sciences company Ondine Biomedical Inc. (AIM: OBI) reported on Wednesday that five Southern Ontario hospitals are deploying the company's Steriwave nasal photodi...
Ionis reports positive Phase 3 sefaxersen data in IgA nephropathy
23 September 2026 - RNA-targeted medicine company Ionis Pharmaceuticals Inc (Nasdaq: IONS) and healthcare company Roche on Wednesday reported positive interim results from the Phase 3 IMAgINATION stud...
X-Chem and Relay Therapeutics collaborate on Phase 3 milestone
23 September 2026 - X-Chem, a US-based global company involved in innovative drug discovery services, announced on Tuesday the achievement of a milestone following Relay Therapeutics' initiation ...